Oric Pharmaceuticals

ORIC

Market cap $1.16B

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025, at 11:15 a.m. ET. Management will also be participating in one-on-one meetings.

Oric Pharmaceuticals (ORIC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety

Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and 20% PSA90 response rate Rapid and deep ctDNA reductions were observed in 76% of patients and ctDNA clearance was observed in 59% of patients, underscoring potential for long-term treatment and survival benefit PSA responses and ctDNA reductions were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide or with darolutamide Both combination regimens continue to demonstrate a safety and tolerability profile compatible with long-term dosing, with the vast majority of adverse events Grade 1 or 2 and consistent with PRC2 and AR inhibition SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced additional efficacy and safety data from the Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC).

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on November 3, 2025 (the “Grant Date”), ORIC granted a total of 18,400 non-qualified stock options and 3,000 restricted stock units to one new non-executive employee who began their employment with ORIC in October 2025.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the publication of a peer-reviewed research paper in Cancer Research, a journal of the American Association for Cancer Research.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating in the following investor conferences in November:

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented posters at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics highlighting preclinical data that further illustrate the potential for ORIC-944, a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit, to treat prostate cancer and various other solid tumors.

ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted stock units to one new non-executive officer employee who began their employment with ORIC in August 2025.